The consultation featured a series of informative sessions aimed at enhancing the global effort to eradicate polio and safeguarding the health of future generations.

Session I provided a comprehensive overview of the current state of the polio eradication program and discussed the rationale for extending the GPEI strategy from 2022 to 2029. This session underscored the ongoing challenges posed by polio outbreaks in conflict-affected regions, including Nigeria, the Democratic Republic of Congo (DRC), and northern Yemen.

Session II focused on the Polio Vaccine Security Framework, emphasizing the collaborative development process that involved valuable feedback from manufacturers, NACs, NRAs, and other partners.

In Session III, representatives from UNICEF, WHO, and GAVI delivered updates on routine immunization and vaccine supply. They discussed the status of the inactivated polio vaccine (IPV) and bivalent oral polio vaccine (bOPV), along with insights into the global IPV market, the rollout of IPV2, and the hexavalent vaccine program.

Session IV highlighted new developments in polio vaccines and products, including evaluations of the 2016 switch from trivalent OPV (tOPV) to bOPV, planning for the cessation of bOPV, GPEI's research and development priorities, and updates on polio vaccine pre-qualification.

Session V was dedicated to poliovirus containment and certification, providing a comprehensive update on progress toward poliovirus containment certification and insights into the status of polio eradication certification at both regional and global levels.

Finally, in Session VI, attendees had the opportunity to hear from partners in the vaccine manufacturing industry. Companies such as CanSino Biologics, Batavia Biosciences, Bio Farma, and PharmaJet shared exciting updates on their innovations, including advancements in virus-like particle (VLP) technology for polio vaccine production, novel OPV2, Sabin-IPV, the HIP-Vax platform designed to reduce manufacturing costs, and needle-free injection technology.

Razi Institute's participation in this consultation underscores its commitment to the global fight against polio and highlights the importance of collaboration among stakeholders in achieving a polio-free world.